Ozempic — Before & After
GLP-1 receptor agonist originally for diabetes, widely used off-label for weight loss.
Real ozempic photos coming soon
We're curating consented, licensed before-and-after images for Ozempic. Until they're live, this page covers the technique, recovery, cost, and what to expect.
What is ozempic?
GLP-1 receptor agonist originally for diabetes, widely used off-label for weight loss.
Also known as semaglutide.
Ozempic by topic
Information pages — cost, recovery, surgeons, and more
Ozempic by recovery timeline
How the result evolves over time
Ozempic by demographic
Age and gender breakdowns of common candidates
Ozempic by ethnicity
Anatomical and aesthetic considerations across patient backgrounds
Ozempic by outcome reality
Range of results — from natural to cautionary
Ozempic by where it's performed
Regional approaches and aesthetic preferences
Frequently asked
How much weight can you lose on Ozempic?
In trials, semaglutide produced an average 15–20% body weight loss at 68 weeks at the highest dose. Tirzepatide (Mounjaro/Zepbound) reaches ~22%. Real-world losses are typically lower.
Does insurance cover Ozempic for weight loss?
Ozempic is approved for type 2 diabetes — covered for those patients. Wegovy (same molecule, weight-loss-approved) is more likely to be covered when prior-authorization criteria (BMI 30+, or 27+ with comorbidities) are met.
What happens when you stop Ozempic?
Most patients regain 60–70% of lost weight within 12 months of stopping without lifestyle changes. The medication suppresses appetite — when it's gone, baseline hunger returns. Plan for either ongoing medication or aggressive lifestyle change at discontinuation.
What is 'Ozempic face'?
Significant facial fat loss with rapid weight loss creates a hollow, prematurely aged appearance — colloquially 'Ozempic face.' Filler (cheek, tear trough, temple) can restore volume. The same effect occurs with any rapid weight loss, not just GLP-1s.
Are GLP-1 medications safe long-term?
Long-term safety data is still accumulating. Major concerns: pancreatitis (rare but serious), gallbladder disease (more common with rapid loss), muscle loss without resistance training, and a theoretical thyroid C-cell tumor risk (boxed warning, never seen in humans). Discuss your specific risk with a prescriber.